Published in Am J Pathol on December 01, 2000
Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res (2004) 3.83
Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci (2008) 3.14
Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol (2008) 1.44
The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res (2012) 1.39
Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc (2008) 1.13
Molecular prognostic testing and individualized patient care in uveal melanoma. Am J Ophthalmol (2009) 1.07
Uveal melanoma. J Skin Cancer (2011) 0.98
Molecular pathology of uveal melanoma. Eye (Lond) (2012) 0.94
PERP expression stabilizes active p53 via modulation of p53-MDM2 interaction in uveal melanoma cells. Cell Death Dis (2011) 0.89
Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. Sci Rep (2016) 0.86
Eye cancer: unique insights into oncogenesis: the Cogan Lecture. Invest Ophthalmol Vis Sci (2006) 0.86
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. Oncotarget (2016) 0.85
Genetics of uveal melanoma and cutaneous melanoma: two of a kind? Dermatol Res Pract (2010) 0.80
High levels of Hdmx promote cell growth in a subset of uveal melanomas. Am J Cancer Res (2012) 0.80
Suppression of thrombospondin-1 expression during uveal melanoma progression and its potential therapeutic utility. Arch Ophthalmol (2012) 0.78
Melanoma epidemiology, biology and prognosis. EJC Suppl (2013) 0.78
Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol (2016) 0.77
Analysis of Bcl-2 protein expression in choroidal melanomas. J Clin Pathol (2005) 0.77
Clinico-Pathological Association of Delineated miRNAs in Uveal Melanoma with Monosomy 3/Disomy 3 Chromosomal Aberrations. PLoS One (2016) 0.76
Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB. Genes Cancer (2016) 0.75
p63 is required beside p53 for PERP-mediated apoptosis in uveal melanoma. Br J Cancer (2016) 0.75
The genetics of uveal melanoma: current insights. Appl Clin Genet (2016) 0.75
Minimal contribution of ERK1/2-MAPK signalling towards the maintenance of oncogenic GNAQQ209P-driven uveal melanomas in zebrafish. Oncotarget (2016) 0.75
Focus on cutaneous and uveal melanoma specificities. Genes Dev (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Cancer cell cycles. Science (1996) 21.29
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (1986) 13.96
BCL-2 family members and the mitochondria in apoptosis. Genes Dev (1999) 13.52
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
Signaling to p53: breaking the MDM2-p53 circuit. Cell (1998) 8.63
Clinical implications of the p53 tumor-suppressor gene. N Engl J Med (1993) 7.29
Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science (1987) 6.93
The p53 pathway. J Pathol (1999) 6.79
Structural evidence for the authenticity of the human retinoblastoma gene. Science (1987) 4.67
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell (1994) 3.69
Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J (1999) 3.41
Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature (1997) 3.10
Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol (2000) 2.84
c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol (1999) 2.50
Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J (1999) 2.31
MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst (1994) 2.06
The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod (1998) 1.83
The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol (2000) 1.76
Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res (1997) 1.70
Malignant melanoma: modern black plague and genetic black box. Genes Dev (1998) 1.67
Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res (1994) 1.57
The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res (1997) 1.35
Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet (1995) 1.17
Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol (1997) 1.16
Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res (1994) 1.15
Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma. Invest Ophthalmol Vis Sci (1999) 1.13
Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol (1998) 1.00
Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res (2000) 1.00
TP53 allele loss, mutations and expression in malignant melanoma. Br J Cancer (1994) 0.99
Association of specific chromosome alterations with tumour phenotype in posterior uveal melanoma. Br J Cancer (2000) 0.95
c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol (1999) 0.95
Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer (1992) 0.92
Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes. Br J Cancer (2000) 0.91
Expression of bcl-2 in uveal malignant melanoma. Arch Pathol Lab Med (1996) 0.87
Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma. Ophthalmology (1997) 0.86
p53 gene and cell cycling in uveal melanoma. Am J Ophthalmol (1996) 0.86
The prognostic significance of c-myc oncogene expression in uveal melanoma. Melanoma Res (1998) 0.86
Genetic aspects of uveal melanoma: a brief review. Semin Oncol (1996) 0.86
C-myc oncogene expression in ocular melanomas. Graefes Arch Clin Exp Ophthalmol (1992) 0.86
Constitutional alterations in p16 in patients with uveal melanoma. Melanoma Res (1996) 0.85
Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components. J Cutan Med Surg (1999) 0.82
Alcoholic liver disease: I. Interrelationships among histologic features and the histologic effects of prednisolone therapy. Hepatology (1982) 0.80
Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell (2000) 4.48
p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosis. Oncogene (2010) 1.06
Clivus chordoma: a report of 12 recent cases and review of the literature. Skull Base Surg (1991) 1.00
Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res (2000) 1.00
Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye (Lond) (2006) 0.99
Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers. Am J Hum Genet (1989) 0.87
The molecular biology of retinoblastoma. Ocul Immunol Inflamm (2001) 0.77
A new mutation with staggering effects. Pigment Cell Melanoma Res (2011) 0.75